Stock ULTI ULTIMOVACS ASA
Add to a list
To use this feature you must be a member
Log inSign up

Financials Ultimovacs ASA

Equities

ULTI

NO0010851603

Biotechnology & Medical Research

Market Closed - Oslo Bors
Other stock markets
 08:15:00 08/05/2024 pm IST 		5-day change 1st Jan Change
7.03 NOK 0.00% Intraday chart for Ultimovacs ASA +0.72% -94.28%
07/05 Transcript : Ultimovacs ASA, Q1 2024 Earnings Call, May 07, 2024
17/04 Ultimovacs to Reduce 40% of Workforce Amid Operational Adjustments MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,092 2,558 3,860 3,784 4,225 241.9 - -
Enterprise Value (EV) 1 692.5 2,117 3,288 3,364 3,962 -1,758 -1,644 -116.1
P/E ratio -17.9 x -21.2 x -22.1 x -22.4 x -22.3 x 0.18 x -3.77 x -17.6 x
Yield - - - - - - - -
Capitalization / Revenue - - - - - - 2.78 x -
EV / Revenue - - - - - - -18.9 x -
EV / EBITDA -10.8 x -17.4 x -20.4 x -18.6 x -18.6 x -1.03 x 22.4 x 1.06 x
EV / FCF -11 x -19.5 x -26.1 x -20 x -20.9 x -1.19 x 21.8 x 1.06 x
FCF Yield -9.12% -5.13% -3.83% -4.99% -4.79% -83.8% 4.59% 94.7%
Price to Book 2.46 x 5.24 x 6.51 x 8.42 x 15.1 x 1.84 x 2.06 x -
Nbr of stocks (in thousands) 27,860 31,974 34,222 34,396 34,406 34,406 - -
Reference price 2 39.20 80.00 112.8 110.0 122.8 7.030 7.030 7.030
Announcement Date 14/02/20 17/02/21 17/02/22 16/02/23 14/02/24 - - -
1NOK in Million2NOK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - 87 -
EBITDA 1 -64.15 -121.4 -161.1 -181 -213 1,707 -73.5 -110
EBIT 1 -66.22 -124.1 -163.8 -183.6 -215.7 1,707 -75 -110
Operating Margin - - - - - - -86.21% -
Earnings before Tax (EBT) 1 -61.17 -120.6 -164.7 -167.8 -189.2 1,707 -72.04 -110
Net income 1 -61.17 -120.6 -164.7 -167.8 -189.2 1,521 -72.04 -110
Net margin - - - - - - -82.8% -
EPS 2 -2.195 -3.770 -5.100 -4.900 -5.500 38.90 -1.862 -0.4000
Free Cash Flow 1 -63.16 -108.5 -125.9 -167.9 -189.9 1,473 -75.5 -110
FCF margin - - - - - - -86.78% -
FCF Conversion (EBITDA) - - - - - 86.29% - -
FCF Conversion (Net income) - - - - - 96.84% - -
Dividend per Share - - - - - - - -
Announcement Date 14/02/20 17/02/21 17/02/22 16/02/23 14/02/24 - - -
1NOK in Million2NOK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 400 441 572 420 263 2,000 1,886 358
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -63.2 -109 -126 -168 -190 1,473 -75.5 -110
ROE (net income / shareholders' equity) -20.2% -25.8% -30.5% -32.2% -51.9% -33% -32.8% -23%
ROA (Net income/ Total Assets) -18.3% -23.9% -27.6% - -44.1% -53.6% -32.5% -
Assets 1 334 503.9 596.3 - 429.4 -2,838 221.6 -
Book Value Per Share 2 16.00 15.30 17.30 13.10 8.120 3.820 3.410 -
Cash Flow per Share - - - - - - - -
Capex - - 0.09 0.2 0.03 - - -
Capex / Sales - - - - - - - -
Announcement Date 14/02/20 17/02/21 17/02/22 16/02/23 14/02/24 - - -
1NOK in Million2NOK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
7.03 NOK
Average target price
6.5 NOK
Spread / Average Target
-7.54%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ULTIMOVACS ASA Stock Ultimovacs ASA
-94.28% 22.18M
MODERNA, INC. Stock Moderna, Inc.
+22.56% 46.71B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.51% 41.52B
LONZA GROUP AG Stock Lonza Group AG
+48.83% 41.8B
CELLTRION, INC. Stock Celltrion, Inc.
-3.42% 29.55B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.13% 25.78B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.44% 19.26B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.45% 11.98B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-0.14% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.47% 12.08B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ULTI Stock
  4. Financials Ultimovacs ASA
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW